Clinical significance of intestinal flora and inflammatory factors in patients with diabetic nephropathy
GUO Shiqiang1 LIU Chunlin1 WU Qingnian2
1. Laboratory of Clinical Research Center, the Sixth Affiliated Hospital of South China University of Technology, Guangdong Province, Foshan 528200, China; 2. Department of Clinical Laboratory, the Sixth Affiliated Hospital of South China University of Technology, Guangdong Province, Foshan 528200, China
Abstract：Objective To investigate the clinical significance of intestinal flora and inflammatory factors in patients with diabetic nephropathy. Methods A total of 101 patients with type 2 diabetes mellius (T2DM) who were hospitalized in the Sixth Affiliated Hospital of South China University of Technology from January to December 2019 were selected as the study subjects. According to the 24 h urinary albumin excretion rate (UAER), they were divided into group A (UAER≤30 mg/24 h, diabetic normal proteinuria, n=49), group B (30 mg/24 h<UAER≤300 mg/24 h, diabetic microproteinuria, n=30) and group C (UAER>300 mg/24 h, diabetic nephropathy, n=22), and 25 healthy subjects were selected as group D at the same time. The difference of intestinal flora was analyzed by traditional bacterial culture method, and the levels of inflammatory factor interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were detected, and the correlation was analyzed. Results The Bifidobacterium and Clostridium in group C were lower than those in group A, group B and group D, and the differences were statistically significant (P<0.05). Lactobacillus in group C was lower than that in group D, and the difference was statistically significant (P<0.05). The levels of IL-6 and TNF-α in group C were higher than those in group A, group B and group D, and the differences were statistically significant (P<0.05). The levels of IL-6 and TNF-α were negatively correlated with Bifidobacterium and Clostridium (P<0.05). Conclusion There are significant differences in intestinal flora in patients with diabetic nephropathy. With the increased expression of inflammatory factors, intestinal flora may mediate the occurrence of inflammation and participate in the occurrence and development of diabetic nephropathy.
Sato J，Kanazawa A，Ikeda F，et al.Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes[J].Diabetes Care，2014，37（8）：2343-2350.
[4]
Vrieze A，Nood EV，Holleman F，et al.Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome[J].Gastroenterology，2012，143（4）：913-916.
[5]
American Diabetes Association.Professional Practice Committee for the Standards of Medical Care in Diabetes-2016[J].Diabetes Care，2016，39（Suppl 1）：S107-S108.
[6]
Inker LA，Schmid CH，Tighiouart H，et al.CKD-EPI Investigators.Estimating glomerular filtration rate from serum creatinine and cystatin C[J].N Engl J Med，2012，367（1）：20-29.
[7]
Ohkusa T，Ozaki Y，Satoc，et al.Long-term ingestion of lactosucrose increases Bifidobacterium sp.in human fecal flora[J].Digestion，1995，56（5）：415-420.
Morrison DJ，Preston T.Formation of short chain fatty acids by the gut microbiota and their impact on human metabo-lism[J].Gut Microbes，2016，7（3）：189-200.
[12]
Marzocco S，Fazeli G，Micco LD，et al.Supplementation of Short-Chain Fatty Acid，Sodium Propionate，in Patients on Maintenance Hemodialysis：Beneficial Effects on Inflammatory Parameters and Gut-Derived Uremic Toxins，A Pilot Study （PLAN Study）[J].J Clin Med，2018，7（10）：315.
[13]
Khan S，Imran A，Malik A，et al.Bacterial imbalance and gut pathologies：Association and contribution of E.coli in inflammatory bowel disease[J].Crit Rev Clin Lab Sci，2019， 56（1）：1-17.
[14]
Wong J，Piceno YM，DeSantis TZ，et al.Expansion of urease-and uricase-containing，indole-and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD[J].Am J Nephrol，2014，39（3）：230-237.
Winther SA，Henriksen P，Vogt JK，et al.Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria[J].Diabetologia，2020，63（12）：2713-2724.
[17]
Yang T，Richards EM，Pepine CJ，et al.The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease[J].Nat Rev Nephrol，2018，14（7）：442-456.
[18]
赵悦，王俭勤.炎症在糖尿病肾病中的研究进展[J].新医学，2021，52（7）：477-481.
[19]
Perraudeau F，McMurdie P， Bullard J，et al.Improvements to postprandial glucose control in subjects with type 2 diabetes：a multicenter，double blind，randomized placebo-controlled trial of a novel probiotic formulation[J].BMJ Open Diabetes Res Care，2020，8（1）：e001319.
[20]
Conteh AR，Huang R.Targeting the gut microbiota by Asian and Western dietary constituents：a new avenue for diabetes[J].Toxicol Res （Camb），2020，9（4）：569-577.
京公网安备 11010502046607号